UK's CRT cooperates with Barcelona Univ
Cancer Research Technology, a UK specialist oncology development and commercialization company, and the University of Barcelona, Spain, have initiated a collaboration to develop AT514 (serratamolide) and analogs for the treatment of cancer. AT514 is a microbial depsipeptide, identified as an anticancer agent by scientists at the University.
The University of Barcelona will conduct development studies in collaboration with CRT and has assigned the rights to the use of AT514 in the treatment of cancer to CRT. Commercialization of AT514 will be led by CRT and both parties will share future revenues.
This is the first collaboration between CRT and the University, and the company hopes that this partnership will result in the generation of an important new cancer therapy and lead to further joint oncology drug development and commercialization projects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze